IKBKE and glioblastoma: All of the above data demonstrated that CYT387 could enhance the activity of the Hippo pathway, which reduced YAP1, TEAD2 and downstream target protein expression, to inhibit glioblastoma progression by suppressing and inactivating IKBKE.